Abstract
The first 3 postpartum months represent a high-risk period for psychiatric illnesses. This article reviews the prevalence and diagnostic criteria for postpartum illnesses, including the "maternal blues," postpartum depression, and postpartum psychosis. Pharmacologic treatment of these disorders is often complicated by a patient's desire to breast-feed, yet there are no controlled trials of antidepressant treatment during lactation. Infant exposure and limitations to monitoring infant sera are reviewed. Lastly, a model and guide for reducing fetal and infant exposures is presented.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Adult
-
Breast Feeding / adverse effects
-
Clinical Trials as Topic
-
Depression, Postpartum / diagnosis*
-
Depression, Postpartum / drug therapy
-
Depression, Postpartum / epidemiology
-
Drug Monitoring
-
Female
-
Fetal Diseases / chemically induced
-
Fetal Diseases / epidemiology
-
Humans
-
Infant, Newborn
-
Maternal Exposure / adverse effects
-
Maternal-Child Nursing
-
Maternal-Fetal Exchange
-
Milk, Human
-
Practice Guidelines as Topic
-
Pregnancy
-
Prevalence
-
Psychotic Disorders / diagnosis
-
Psychotic Disorders / drug therapy
-
Psychotic Disorders / epidemiology
-
Puerperal Disorders / diagnosis
-
Puerperal Disorders / drug therapy
-
Puerperal Disorders / epidemiology
-
Reproducibility of Results
-
Risk Factors
-
Terminology as Topic